Detection of cognitive decline using a single-channel EEG system with an interactive assessment tool

Lior Molcho[†1], Neta B. Maimon[†1,2], Narkiss Pressburger[1], Noa Regev-Plotnik[3], Sarit Rabinowicz[3], Nathan Intrator[4,5], Ady Sasson[3].

[1] Neurosteer Ltd., Herzliya, Israel.

[2] The School of Psychological Sciences, Tel Aviv University, Tel Aviv, Israel.

[3] Dorot Geriatric Medical Center, Netanya, Israel.

[4] Blavatnik School of Computer Science, Tel-Aviv University, Tel-Aviv, Israel; Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.

[5] Neurosteer Inc., New-York, NY, USA.

[†]These authors contributed equally to this work.

Abstract

Background: Cognitive decline remains highly underdiagnosed in the community despite extensive efforts to find novel biomarkers to detect it. Finding objective screening tools for cognitive decline may improve early diagnosis of Alzheimer's disease (AD) in the community. EEG biomarkers based on machine learning (ML) may offer a noninvasive low-coast approach for identifying cognitive decline with clinically useful accuracy. However, most of the studies use multi-electrode systems which are not vastly accessible. This study aims to evaluate the ability to extract cognitive decline biomarkers using a wearable single-channel EEG system with a short interactive cognitive assessment tool.

Methods: Seniors in different clinical stages of cognitive decline (healthy to mild dementia, n=60) and young healthy participants (n=22) performed a cognitive assessment which included auditory detection and resting state tasks, while being recorded with a single-channel EEG (Aurora by Neurosteer®). Seniors' MMSE scores were obtained by clinicians and used in allocating the groups (Healthy: MMSE$\geq$28; MCI-R: 28>MMSE$\geq$24; and MD: MMSE<24). Data analysis included standard frequency bands as well as three novel biomarkers, A0, ST4 and VC9, previously extracted from a different dataset to minimize overfitting risks.

Results: Correlation between MMSE scores and reaction times was significant, validating the cognitive assessment tool. Individual MMSE scores correlated significantly with two of the EEG biomarkers: A0 and ST4. Furthermore, A0 and ST4 showed significant separation

between groups of seniors with high vs. low MMSE scores, as well as the healthy young group. ST4 separated between the healthy groups (young and seniors) and the low MMSE (MD) group. Conversely, A0 differentiated between the healthy young group and all three groups of seniors. In the healthy young group, activity of Theta band and VC9 biomarker significantly increased with higher cognitive load, with both separating between the high cognitive load task and resting state. Furthermore, VC9 showed a finer separation between high and low cognitive load levels within the cognitive task. This was not shown in the senior groups, suggesting VC9 may be indicative to cognitive decline in the senior population.

Conclusions: These results introduce novel biomarkers which potentially detect cognitive decline, obtained by a wearable single-channel EEG with a short interactive cognitive assessment. Such objective screening tools can be used on a large scale to detect cognitive decline and potentially allow early diagnosis of AD in every clinic.

Introduction

Dementia is gradually recognized as one of the most significant medical challenges of the future. So much so, that it has already reached epidemic proportions, with prevalence roughly doubling every five years over the age of 65 [1]. This rate is expected to increase unless therapeutic approaches are found to prevent or stop disease progression [2].

Since Alzheimer's Disease (AD) is the most prevalent form of dementia, responsible for about 60–70% of cases [3], it remains the focus of clinical trials. To date, most clinical trials that include a disease-modifying treatment, fail to demonstrate clinical benefits in symptomatic AD patients. This could be explained by the late intervention that occurs after neuropathological processes have already resulted in substantial brain damage [4]. Interventions starting early in the disease process, before substantial neurodegeneration has taken place, can change the progression of the disease dramatically [5]. Cognitive decline is an early sign and is highly likely to lead to some form of dementia and specifically AD [6]. Hence, the discovery of predictive biomarkers for preclinical or early clinical stages such as cognitive decline is imperative [7].

Yet, there is still no single, universally recommended screening tool that satisfies all needs in the detection of cognitive impairment [8]. The current recommendation includes review of patient Health Risk Assessment (HRA) information, patient observation and use of

structured cognitive assessment tools, prevalently the Mini-Mental State Examination (MMSE) [9]. The MMSE evaluates cognitive function, producing a total possible score of 30 points. Based on this scoring system patients who score below 24 would typically be suspected for cognitive decline or dementia [10].

Extensive research is now focusing on biomarkers assessing early signs of AD, including quantifiable parameters of blood or CSF [11] [12] [13] [14], non-cognitive symptoms such as impairment of speech, olfaction, pupil light response, retinal vasculature and gait that may serve as phenotypic markers of preclinical AD [15], as well as imaging and neurophysiological technologies [16] [17]. These methods show promising results in research but are not yet available in every clinic. Although these methods largely support the diagnostic process in clinical practice, most are currently applicable only after the onset of clinical symptoms, which typically reflects considerable progression of disease [18]. Furthermore, such methods are invasive, time consuming for the patient and the clinical staff, and very expensive, making them unsuitable for large scale preventive screening for high-risk populations [15].

Naturally, a cognitive assessment using objective brain activity measurements would be preferable to a subjective evaluation using pen-and-paper assessment tools in clinics. Electroencephalography (EEG) biomarkers offer a noninvasive, automatically analyzed and relatively inexpensive screening tool for early diagnosis [19]. Novel diagnostic classification based on the EEG signal could be useful for differentiating between clinical stages [20].

Traditional EEG biomarkers show ambiguous results in studies [19] [21] [22]. However, the development of machine learning (ML) has largely contributed to the extraction of useful information from the raw EEG signal using only mathematical algorithms [23]. Novel techniques are capable of exploiting the large amount of information on time-frequency processes in a single recording [24] [25]. Recent studies demonstrated novel measures of EEG for identification of early AD with clinically useful accuracy, using classifiers based on neural networks, wavelets, and blind source separation, indicating the relevance of such methods for early diagnosis [26] [27] [28] [29] [30]. However, most studies in this field are still initial and have several constraints. In terms of the data analysis, the risk of overfitting the data in classification studies should be addressed in order to ensure generalization capabilities, especially if the sample size is small. Studies that use the same data set for training and extracting the features [20] [31] [32], extend the risk of overfitting.

Furthermore, correlating the extracted classifiers with standard clinical evaluation (e.g. MMSE) or behavioral results of cognitive tests (such as reaction times and accuracy) may help to further validate the novel results with well-established parameters. In terms of data collection, most of the studies in this field use multichannel EEG systems to characterize cognitive decline. The difficulty with high-density multichannel EEG is the long set up time which require specifically trained technicians, making the systems costly and not portable and thus, not suitable for wide-range screening in every clinic. This emphasizes the need for additional cost-effective tools with a short assessment time, allowing detection of subjects in the preclinical or early clinical stages of AD in the community.

In this study we present an easy-to-use wearable EEG system with an interactive cognitive assessment, that has the potential to detect cognitive decline for early AD diagnosis. The system uses auditory stimuli, and extracts biomarkers using harmonic analysis and machine learning methods from a single-EEG-channel. The pre-extracted biomarkers used in this study were discussed in a previous study performed on young healthy subjects [33]. Here, we correlate these biomarkers to behavioral parameters as well as MMSE scores of seniors. This study aims therefore to evaluate the ability of the system to extract cognitive decline biomarkers for early AD diagnosis, recognizing the importance of providing an accurate low-cost alternative for early detection.

Methods

Participants

Senior participants

Ethical approval for this study was granted by the Ethics Committee (EC) of Dorot Geriatric Medical Center on July 01, 2019. Clinical Trials Registry URL: https://clinicaltrials.gov/ct2/show/NCT04386902?term=Neurosteer&draw=2&rank=1

Sixty patients from the inpatient rehabilitation department at Dorot Geriatric Medical Center were recruited to this study. For the full demographic details see Table 1. The overall mean age was 77.55 (9.67) years old. There was a wide range of ages for each group with no significant age difference between the groups. Participants consisted of 47% females and 53% males. Potential subjects were identified by the clinical staff during their admission to the inpatient rehabilitation department. All subjects were hospitalized at the center and were chosen based on inclusion criteria specified in the study protocol. The patients undergo a

Mini Mental State Examination (MMSE) by an Occupational Therapist upon hospital administration and this score was used for screening patients to include those that have scores between 10-30. All subjects were also evaluated for their ability to hear, read, and understand instructions for discussion of Informed Consent Form (ICF) as well as for the auditory task. Patients that speak English, Hebrew, and Russian were provided with the appropriate ICF and auditory task in the language they could read and understand. All participants provided ICF according to the guidelines outlined in the Declaration of Helsinki. Patients that showed any verbal or non-verbal form of objection were not included in the study. Other exclusion criteria included MMSE score lower than 10, presence of several comorbidities, damage to integrity of scalp and/or skull and skin irritation in the facial and forehead area, significant hearing impairments, and history of drug abuse.

In total, 50 of the 60 patients recruited, completed the auditory task and their EEG data was used. 10 patients signed the ICF and were included in the overall patient count but were excluded from data analysis due to their desire to stop the study or technical problems in the recording. The participants were divided into 3 groups; 17 patients with a score of 17-23 in the Mild Dementia (MD) group, 16 patients with a score of 24-27 in the Mild Cognitive Impairment Risk (MCI-R) group and 17 patients with a score of 28-30 in the Healthy group. See table 1 for demographic information.

Group	Healthy	MCI-R	MD
MMSE scores	28-30	24-27	17-23
n	17	16	17
MMSE	28.88 (0.78)	25.64 (0.66)	20.46 (2.06)
Age	74.77 (8.05)	75.42 (7.36)	79.26 (8.57)
Sex, F(%)	13 (81.25)	9 (56.25)	5 (29.41)

Table 1. Demographic information of the senior groups included in the analysis.

Healthy young participants

22 healthy students participated in this study for course credit. The overall mean age was 24.09 (2.79) years old. Participants consisted of 60% females and 40% males. Ethical approval for this study was granted by Tel-Aviv University ethical committee 27.3.18.

Apparatus

<u>EEG device</u>

EEG recordings were performed using a single channel EEG system (Aurora Neurosteer Inc). A 3-electrode medical-grade patch was placed on the subject's forehead using dry gel for optimal signal transduction. The electrodes were located at Fp1 and Fp2 and a reference electrode at Fpz. EEG signal was amplified by a factor of a 100 and sampled at 500 Hz. Signal processing was done in the Neurosteer cloud, for further details see Appendix A.

<u>EEG Recording and Auditory battery</u>

The recording room was quiet and illuminated. The research assistant set up the sanitized system equipment (electrode patch, sensor, EEG monitor, clicker) and provided general instructions to the participants before starting the task. Then the electrode was placed on the subject's forehead and the recording was initiated. The participant was sitting during the assessment and heard instructions through a loudspeaker connected to the EEG monitor. The entire recording session typically lasted 20-30 minutes. The cognitive assessment battery was pre-recorded and included a detection task as well as answering a series of true/false questions by pressing on a wireless clicker button. Further explanations for the task were kept at a minimum to avoid bias. A few minutes of baseline activity were recorded to ensure an accurate test. The auditory cognitive assessment lasted 18 minutes.

<u>Detection Task</u>

Figure 1 illustrates the detection task used in the study. In each block, participants were presented with a sequence of melodies (played by a violin, a trumpet, and a flute). The participants were given a clicker to respond to the stimuli. In the beginning of each block, auditory instructions indicated an instrument to which the participant responded by clicking once. The click response was only to "yes" trials, when the indicated instrument melody had played. The task included two difficulty levels to test increasing cognitive load. In level 1, each melody was played for 3 seconds, and the same melody repeated throughout the entire block. The participant was asked to click once as fast as possible for each repetition of the melody. In level 2, the melodies were played for 1.5 seconds, and all three instruments appeared in the block. The participants were asked to click only for a specific instrument within the block and ignore the rest of the melodies.

Figure 1. An example of six trials of detection level 1 (top) and detection level 2 (bottom). Both examples show a "Trumpet block" in which the participant reacts to the trumpet melody. Red icons represent trials in which the participant was required to respond with a click when hearing the melody, indicating a "yes" response.

Data Analysis

Construction of Brain Activity Features and Classifiers

The signal processing algorithm interprets the EEG data using a time/frequency wavelet-packet analysis, which characterizes different components by their fundamental frequency and corresponding higher harmonics. In addition, standard spectral analysis of the signal was used to produce the classical EEG frequency bands.

The optimal number of different features was determined on a large dataset using unsupervised Machine Learning techniques (i.e. ML extracting features on unlabeled data). This analysis resulted in 121 Brain Activity Features (BAFs) [34] [35]. The BAFs activity can be regarded as a series of vectors with 121 values that are sampled every second. Combinatorically, there are millions of linear and non-linear combinations that can be created out of these long vectors. Prior to this examination, several such combinations were computed using ML. These combinations were calculated from data of healthy subjects performing different tasks in different difficulty levels. The labelled data was used to train linear and non-linear classifiers that differentiate between different tasks. The value of each feature was calculated once every second from a moving window of 4 seconds. Three of those biomarkers were described in a previous study on healthy subjects performing a well-validated cognitive task (i.e. n-back task) [33]. The biomarkers exhibited separation between different levels of cognitive load and therefore were the most relevant for the present study. The full technical specifications regarding the construction of these features and the extractions of the biomarkers are provided in Appendix A.

<u>Dependent variables</u>

<u>Behavioral measurements</u>

The behavioral dependent variables included mean response accuracy and mean reaction time (RT) per participant, for correct responses only.

<u>Electrophysiological variables</u>

The electrophysiological dependent variables included the power spectral density. Absolute power values were converted to logarithm base 10 to produce values in dB. The following frequency bands were included: Delta (0.5-4 Hz), Theta (4–7 Hz), Alpha (8–15 Hz), Beta (16–31 Hz), and lower Gamma (32–45 Hz).

The BAFs analysis included the activity of the three selected biomarkers: ST4, A0, and VC9 normalized to a scale of 0-100. The EEG variables were calculated per each second from a moving window of 4 seconds, and mean activity per condition was taken into the analyses.

<u>Statistical analyses</u>

Five statistical analyses were performed on the dependent variables in three parts. Data of the 50 senior participants and their individual MMSE scores were included in the first two parts of the analyses (1 and 2). The third part included all study data (seniors and young healthy controls, see Figure 2).

The purpose of the first analysis was to confirm the validity of the detection task. It was assumed based on previous studies [5] that Reaction Times (RTs) would be higher for participants with lower MMSE scores. This was tested by calculating the Pearson correlation between mean RTs in detection levels 1 and 2, and the individual MMSE score of each participant. Additionally, correlations were calculated between RTs and the EEG variables.

The second analysis was performed to find which of the EEG variables correlated with the previously assigned MMSE score of each participant. For this purpose, Pearson correlation was calculated using the mean activity of the EEG variables during the detection task and each individual MMSE score.

For the third analysis, data of the 50 senior participants was divided into three groups according to the MMSE scores. The groups were allocated as follows (see Figure 2): Mild Dementia (MD) group with MMSE<24, Mild Cognitive Impairment Risk (MCI-R) group with 24$\geq$MMSE<28, and Healthy Seniors with MMSE$\geq$28. We used MMSE score cutoffs

of 24 and 27 in allocating the groups, as we are mostly interested in very early detection of AD and MCI, and found previous indications that a higher cutoff score would achieve optimal evaluations of diagnostic accuracy [36]. Furthermore, it was argued that educated individuals who score below 27 are at greater risk of being diagnosed with dementia [37]. An ANOVA analysis was conducted for each of the EEG variables, with group as a between-participant independent variable. A linear trend analysis was also performed on the three groups.

Finally, to examine the differences in activity patterns between the groups of senior participants and healthy young controls, a repeated-measures ANOVA was conducted on each of the EEG variables with task level (detection levels 1 and 2 and resting task) as within participants variable, and group as between participant variable. The groups were allocated as before with an addition of the young healthy group (see Figure 2). A resting state task was included as well to test the differences between a passive condition (resting) and an active condition (task elicited cognitive load). Significance level was p<0.05, and post-hoc analyses were calculated with Bonferroni correction. A linear trend analysis was also performed on the four groups. Data was analyzed with Python SciPy [38] and R studio (R Foundation for Statistical Computing).

Figure 2. Study design and groups at each stage. The study included both seniors and young participants as controls. For the senior participants, an MMSE score was obtained, and division into groups was based on the individual MMSE score.

Results

Validation of behavioral task

The correlations between individual MMSE scores and participants' Reaction Times (RTs) in both levels of the detection task was significant, both for each level separately as well as the mean activation in the entire cognitive detection task (p<.01 for all, see Table 2). Additionally, mean RTs were calculated for each participant and each task. A0 biomarker activity significantly increased with slower participant reaction times, and ST4 biomarker activity significantly decreased with slower reaction times (see Table 3 and Figure 3).

Task level	Detection 1	Detection 2	Mean
r	-.535**	-.423**	-.519**
p	**<.001**	**0.005**	**<.001**
df	49	43	49

Table 2. Results of Pearson correlation between individual MMSE scores and reaction times (RTs) for the cognitive detection task (levels 1 and 2) and mean reaction times. Significant effects are marked in bold.

Feature	Alpha	Beta	Delta	Gamma	Theta	A0	VC9	ST4
r	0.198	0.194	0.037	0.183	0.000	0.264	-0.036	-0.252
p	0.058	0.064	0.728	0.081	0.997	**0.011**	0.732	**0.016**

Table 3. Pearson correlation analysis between individual mean RTs (detection 1 and detection 2), and EEG variables activity. Significant effects are marked in bold.

Figure 3. Correlation between individual A0 (right) and ST4 (left) biomarkers activity during detection task, and individual mean reaction times. A0 biomarker shows significantly increased activity with slower participant reaction times, while ST4 biomarker shows significantly decreased activity with slower reaction times.

Correlations between MMSE scores and EEG variables

For statistical values of all EEG variables see Table 4. The activity of A0 increased for lower MMSE score while the activity of ST4 decreased for lower MMSE score (p=.010 and p=.009, respectively, see Table 4 and Figure 4).

Feature	Alpha	Beta	Delta	Gamma	Theta	A0	VC9	ST4
r	-0.1111	-0.2430	0.0773	-0.2269	0.1439	-0.3570	0.0930	0.3617
p	0.4423	0.0891	0.5938	0.1130	0.3187	**0.0109**	0.5204	**0.0099**

Table 4. Pearson correlation analysis between individuals MMSE scores and mean activity of the EEG variables during the detection task. Significant effects are marked in bold.

Figure 4. Correlation between A0 (left) and ST4 (right) biomarkers activity (during the cognitive detection task per participant) and individual MMSE score (n=50). A0 biomarker shows significantly increased activity for lower MMSE score, while ST4 biomarker shows significantly decreased activity for lower MMSE score.

Comparison between three groups of senior patients

For a full description of the F values, p values and effect size (η_p^2) of all statistical tests in the ANOVA see Table 5. Biomarkers A0 and ST4 showed a significant main effect for group between the three groups of senior patients with p=.048 and p=.011 respectively (see Figure 5). Activity of A0 biomarker increased while activity of ST4 biomarker decreased for the lower functionality group (MD). Post-hoc analyses using Bonferroni corrections revealed a significant difference between Healthy and MD groups for A0 and ST4 (p=.037 and p=.008 respectively) during performance of a cognitive detection task. Additionally, a linear trend between the three groups (e.g. Healthy, MCI-R and MD) was significant for A0 and ST4 with p=.014 and p=.003 respectively.

Figure 5. Mean A0 (left) and ST4 (right) activity during the detection task for the Healthy (blue), MCI-R (orange) and MD (grey) groups. A0 shows lower activity, while ST4 shows higher activity for the healthy group, differentiating it from the MD group. Brackets present post-hoc analysis with Bonferroni correction, bold bracket presents main effect. A linear trend was observed for both biomarkers between the three groups. Data is presented as mean and SEM.

Comparison between senior patients and healthy young controls

For a full description of the F values, p values and effect size (η_p^2) of all statistical tests in the ANOVA see Table 5. The main effect for group was significant for A0 and ST4 ($p<.001$ and $p=.005$ respectively). Post-hoc analysis with Bonferroni corrections showed that activity of the healthy young participants was significantly lower than each of the other three senior groups for A0 biomarker ($p<.001$ for all comparisons). Additionally, A0 biomarkers showed significant separation within the senior population between the MD group and Healthy seniors group ($p=.027$). Higher activity was observed for ST4 for the healthy young group and the healthy seniors group compared to the MD group ($p=.007$ and $p=.012$ respectively). Moreover, a linear trend between the four groups was significant for A0 and ST4 ($p<.001$ and $p=.001$ respectively).

Figure 6. Mean biomarkers A0 (left) and ST4 (right) activity during the detection and resting state tasks for the Healthy young (yellow) Healthy seniors (blue), MCI-R (orange) and MD (grey) groups. Brackets present post-hoc analysis with Bonferroni correction, bold bracket presents main effect. A linear trend was observed for both biomarkers between the four group. Data is presented as mean and SEM.

Comparison between detection and resting state tasks

For a full description of the F values, p values and effect size (η_p^2) of all statistical tests in the ANOVA see Table 6. When measuring the differences between the three task levels: detection 1, detection 2 and resting state, across the healthy young group (n=22) and mean of all three groups of seniors that performed all three tasks (n=43), both Theta band and VC9 biomarker showed significant difference between the tasks (*p*=.007 and *p*<.001, respectively). Pairwise comparisons reveled that for Theta band the difference between detection 2 (highest cognitive load) and resting state task was significant (*p*=.001). For VC9, the difference between detection 2 (highest cognitive load) and resting state was significant (*p*=.001), as well as the difference between levels within the cognitive task (detection levels 1 vs. 2, *p*=.019). For both Theta band and VC9 biomarker, this difference between the tasks was present only in the young healthy group and insignificant for the three senior groups. Significant main effect is shown for Theta band and VC9, when calculated separately including only the young healthy group (*p*<0.01 for both, see Figure 7).

Figure 7. Mean activity of Theta band (top) and VC9 biomarker (bottom) comparing between the tasks: detection 2 (dark green, high cognitive load), detection 1 (green, low cognitive load) and resting state (light green), for healthy young controls and mean across all three groups of seniors. Brackets present post-hoc analysis with Bonferroni correction, bold bracket presents main effect for healthy young group only. Data is presented as mean and SE with Morey's correction [39].

	ANOVA results between 3 groups of seniors (cognitive detection task)						ANOVA results between 4 groups including seniors and young healthy (cognitive and resting state task)					
EEG Variable	Type III SS	df	Mean Square	F	Sig.	η_p^2	Type III SS	df	Mean Square	F	Sig.	η_p^2
Alpha	5.995	2	2.998	0.578	0.565	0.024	33.63	3	11.21	2.348	0.08	0.094
Beta	35.58	2	17.79	1.062	0.354	0.043	43.889	3	14.63	1.03	0.385	0.043
Delta	28.991	2	14.495	0.799	0.456	0.033	45.208	3	15.069	0.958	0.418	0.041
Gamma	45.054	2	22.527	1.051	0.358	0.043	55.217	3	18.406	1.013	0.392	0.043
Theta	23.611	2	11.805	0.945	0.396	0.039	24.699	3	8.233	0.745	0.529	0.032
A0	526.155	2	263.077	3.358	**0.043**	0.125	4362.476	3	1454.159	23.98	**<.001**	0.514
VC9	55.362	2	27.681	0.668	0.518	0.028	224.401	3	74.8	2.061	0.114	0.083
ST4	373.146	2	186.573	4.764	**0.013**	0.169	502.587	3	167.529	4.749	**0.005**	0.173

Table 5. The F values, p values and effect size (η_p^2) of the ANOVA analyses with group as between-participant variable. The ANOVA results on the left are between the three groups of senior participants performing the cognitive detection task. The ANOVA results on the right are between the healthy young group and the three senior groups performing the detection and resting state tasks. Significant main effects are marked in bold.

ANOVA within participants (all 4 groups, difference between the 3 tasks)						
EEG Variable	Type III SS	df	Mean Square	F	Sig.	η_p^2
Alpha	0.731	2	0.365	0.181	0.835	0.003
Beta	5.361	2	2.681	1.053	0.352	0.017
Delta	29.259	2	14.63	2.767	0.067	0.043
Gamma	8.16	2	4.08	1.248	0.291	0.02
Theta	39.37	2	19.685	5.143	**0.007**	0.078
A0	31.647	2	15.823	1.675	0.191	0.027
VC9	159.547	2	79.773	8.687	**<.001**	0.125
ST4	59.112	2	29.556	2.131	0.123	0.034

Table 6. The F values, p values and effect size (η_p^2) of the within-participants repeated measures ANOVA (all four groups of Healthy young, Healthy seniors, MCI-R and MD) between the tasks: detection (level 1 and 2) and resting state. Significant main effects are marked in bold.

Discussion

Cognitive decline remains highly underdiagnosed in the community [40]. As cognitive decline is an early sign of AD, it would be beneficial to improve the detection rate in the community to allow early intervention. The aim of this study was to evaluate cognitive decline using novel biomarkers extracted with a wearable single-channel EEG sensor. We demonstrate that a short evaluation, which can be self-administered and performed in every clinic, may provide an objective assessment tool for early signs of AD, and potentially offer an alternative to the commonly used Mini-Mental State Examination (MMSE) [9].

60 seniors were recruited to this study and participated in a short and automatic cognitive assessment battery. 50 participants finished the full assessment and were included in data analysis. Classical EEG frequency bands were used in the analysis of the data as well as pre-defined ML features. Machine Learning (ML) applied on raw EEG signals is increasingly being used for early diagnosis of AD. The biomarkers that are extracted using ML approaches show accurate separation between healthy and cognitively impaired populations [27] [28] [30] [41]. Our approach utilizes advanced wavelet-packet analysis [42] [43] as pre-processing to ML. The biomarkers used here were calculated on a different dataset to avoid the risks associated with classification studies such as overfitting [44]. This is unlike other studies that use classifiers trained and tested via cross validation on the same dataset [20] [31] [32]. Specifically, the pre-extracted biomarkers used here, ST4 and VC9, were previously considered in a study performed on young healthy subjects. Results showed a correlation of VC9 to working memory load and correlation of ST4 to individual performance [33].

A novel interactive cognitive assessment based on auditory stimuli with three cognitive load levels (high, low and rest) was used to probe different cognitive states. Individual response performance in the tasks (i.e. reaction times) was correlated to the MMSE score which further validates the cognitive assessment tool. Importantly, individual response performance also significantly correlated with A0 and ST4 biomarkers. These results support previous findings that recording EEG during active engagement in cognitive and auditory tasks offer distinct features and may lead to better discrimination power of brain states [23] [45]. To continue this notion, we used an auditory assessment battery with musical stimuli. It was previously shown that musical stimuli elicit stronger activity than using visual cues such as digits and characters [46].

Results further show that A0 and ST4 significantly correlated with individual MMSE scores. To get a clearer separation between cognitive stages, we divided the participants to groups according to the MMSE scores. In allocating the groups, we used the common cutoff score of 24 to divide between low-functioning (MMSE<24) and high-functioning participants, however, we divided the high-functioning group further using a cutoff score of 27. This was inspired by the debate in the literature over cognitive functionality of patients with scores below 27 [37] [47].

Results demonstrated the ability of A0 and ST4 to significantly differentiate between groups of seniors with high vs. low MMSE scores, as well as the healthy young group. Specifically, ST4 separated between the healthy groups, namely, the healthy young and healthy senior groups, and the low MMSE group (MD group). Conversely, A0 showed differences between the healthy young group and all three groups of seniors (all with p>0.01). A linear trend was found between the four groups, where the healthy young participants are at the one end, and the cognitively impaired MD group at the other end. These results may suggest different cognitive functionality between healthy young participants and healthy seniors. Importantly, A0 also showed more delicate differences between lower and higher MMSE senior groups, separating between the lowest MMSE group (MD group) and the healthy seniors group, with a cutoff score of 24, comparable to previous reports in this field [48] [26] [31]. Moreover, a linear trend was shown between the three groups of seniors, suggesting that the activity of the MCI-risk (MCI-R) group is a midpoint between the cognitively impaired and the cognitively healthy senior groups. This may indicate a different cognitive functionality stage in between entirely healthy seniors and MD patients. Together, these results provide initial indication of the ability of the proposed assessment to detect early signs of AD in the elderly population.

Both biomarkers showed ability to differentiate between different cognitive sates using only a single channel and a short assessment battery, unlike most studies attempting to assess cognitive decline which use multichannel EEG systems [27] [41] [49]. It has been argued that the long setup time of multichannel EEG systems may cause fatigue, stress, or even change mental states, affecting EEG patterns and subsequently study outcomes [32]. This suggests that cognitive decline evaluation using a wearable (one-channel) EEG with a quick setup time may not only make the assessment more affordable and accessible but also potentially reduce the effects of the pretest time on the results. Using a single EEG channel was previously shown to be effective in detection of cognitive decline [48], however, here

we demonstrate results of early detection of AD using biomarkers that were extracted on an independent dataset.

With regards to the classical frequency bands, which were also extracted and tested in this study, theta activity increased with higher cognitive load, separating between high cognitive load and resting state tasks in the young healthy group. This is in line with previous reports [50] [51]. This difference was not present in the senior population, suggesting that theta may be indicative to cognitive decline and serve as a predictor of AD status, consistent with previous findings [20] [52] [53]. VC9 biomarker showed similar separation between high cognitive load and resting state, as well as a significant difference between high and low cognitive load levels within the cognitive task. Therefore, VC9 can be referred to as a refinement of theta indication, supporting previous work validating VC9 as a working memory load biomarker in the healthy population [33].

While the study shows promising results, more work is needed. Specifically, additional studies should include a longer testing period to quantify the variability within subjects and potentially increase the predictive power. Also, larger cohorts of patients that are quantified by extensive brain scanning methods would offer an opportunity to get more sensitive separation between earlier stages of cognitive decline using the suggested tool, and potentially reduce the subjective nature of the MMSE test. Moreover, a longitudinal study using the suggested tool could assess cognitive state in asymptomatic elderly patients and follow participants over time. Additionally, since cognitive decline could be an early symptom of several conditions, a follow up study should consider testing comorbidities to other neurological conditions.

In conclusion, this study presents the results obtained with a self-administered single-channel EEG system for detection of cognitive decline. Using an automatic and low-cost approach, it can provide objective biomarkers and consistency in assessment across patients and between medical facilities clear of tester bias. Furthermore, due to a short set-up time and interactive cloud-based assessment, this tool can be used on a large scale in every clinic and test participants before clinical symptoms emerge and may potentially be used for early detection of cognitive decline.

References

[1] Van der Flier WM, Scheltens P, "Epidemiology and risk factors of dementia," *Journal of Neurology, Neurosurgery & Psychiatry,* vol. 76, pp. 2-7, 2005.

[2] Hebert LE, Weuve J, Scherr PA, Evans DA, "Alzheimer disease in the United States (2010-2050) estimated using the 2010 census," *Neurology,* vol. 80, no. 19, p. 1778-1783, 2013.

[3] Qiu C, Kivipelto M, von Strauss E, "Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention," *Dialogues Clin Neurosci,* vol. 11, no. 2, pp. 111-128, 2009.

[4] Galimberti D, Scarpini E, "Disease-modifying treatments for Alzheimer's disease," *Ther Adv Neurol Disord,* vol. 4, no. 4, p. 203-216, 2011.

[5] Silverberg NB, Ryan LM, Carrillo MC, et al, "Assessment of cognition in early dementia. Alzheimers Dement," *Alzheimers Dement,* vol. 7, no. 3, p. 60-76, 2011.

[6] Ritchie K, Touchon J, "Mild cognitive impairment: conceptual basis and current nosological status," *The Lancet,* vol. 355, no. 9199, pp. 225-228, 2000.

[7] Jack CR Jr, Albert MS, Knopman DS, et al, "Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease," *Alzheimers Dement.,* vol. 7, no. 3, p. 257-262, 2011.

[8] Cordell CB, Borson S, Boustani M, Chodosh J, Reuben D, Verghese J, Thies W, Fried LB, "Alzheimer's Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting," *Alzheimer's & Dementia,* vol. 9, no. 2, pp. 141-150, 2012.

[9] Folstein MF, Folstein SE, McHugh PR, ""Mini-mental state". A practical method for grading the cognitive state of patients for the clinician," *Journal of Psychiatric Research,* vol. 12, no. 3, p. 189–198, 1975.

[10] Tombaugh TN, McIntyre NJ, "The Mini-Mental State Examination: a comprehensive review," *Journal of the American Geriatrics Society,* vol. 40, no. 9, p. 922-35, 1992.

[11] Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al, "Clinical and biomarker changes in dominantly inherited Alzheimer's disease," *N Engl J Med,* vol. 367, p. 795–804, 2012.

[12] Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TL, et al, "Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease," *Sci Transl Med,* vol. 6, pp. 226-30, 2014.

[13] Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, et al, "Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease," *Neurology,* vol. 79, p. 897–905, 2012.

[14] Doecke J, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, et al, "Blood-based protein biomarkers for the diagnosis of Alzheimer's disease," *Arch Neurol,* vol. 69, p. 1318–25, 2012.

[15] Laske C, Sohrabi HR, Frost SM, Lopez-De-Ipina, Garrard P ,Buscema M, et al, " Innovative diagnostic tools for early detection of Alzheimer's disease," *Alzheimers Dementia,* vol. 11, p. 561–78, 2015.

[16] Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al, "Tau PET imaging in aging and early Alzheimer's disease," *Ann Neurol,* vol. 79, p. 110–9, 2016.

[17] Woodard JL, Seidenberg M, Nielson KA, Smith JC, Antuono P, Durgerian S, Guidotti L, Zhang Q, Butts A, Hantke N, Lancaster M, Rao SM, "Prediction of cognitive decline in healthy older adults using fMRI," *Journal of Alzheimer's disease,* vol. 21, no. 3, p. 871–885, 2010.

[18] Urbanelli L, Magini A, Ciccarone V, et al, "New perspectives for the diagnosis of Alzheimer's disease," *Recent Pat CNS Drug Discov,* vol. 4, p. 160–181, 2009.

[19] Cassani R, Estarellas M, San-Martin R, Fraga FJ, Falk TH, "Systematic review on resting-state EEG for Alzheimer's disease diagnosis and progression assessment," *Disease markers,* 2018.

[20] Farina FR, Emek-Savas DD, Rueda-Delgado L, Boyle R, Kiiski H, Yener G, Whelan R, "A comparison of resting state EEG and structural MRI for classifying Alzheimer's disease and mild cognitive impairment," *NeuroImage,* vol. 215, p. 116795, 2020.

[21] Besthorn C, Zerfass R, Geiger-Kabisch C, Sattel H, Daniel S, Schreiter-Gasser U, Förstl H, "Discrimination of Alzheimer's disease and normal aging by EEG data," *Electroencephalography and Clinical Neurophysiology,* vol. 103, no. 2, p. 241–248, 1997.

[22] Bach L, McCulloch J, Hunter, R, "The single EEG in Alzheimer's disease: what value for prognosis," *Int. J. Geriatr. Psychiatry,* vol. 8, pp. 327-330, 1993.

[23] Dauwels J, Vialatte F, and Cichocki A, "Diagnosis of Alzheimer's disease from EEG signals: where are we standing?," *Current Alzheimer Research,* vol. 7, no. 6, p. 487–505, 2010.

[24] Pritchard WS, Duke DW, Coburn KL, Moore NC, "EEG-based, neural-net predictive classification of Alzheimer's disease versus control subjects is augmented by non-linear EEG measures," *Electroencephalogr Clin Neurophysiol,* vol. 91, p. 118–30, 1994.

[25] Babiloni C, Binetti G, Cassetta E, Cerboneschi D, Dal Forno G, Del Percio C, et al, "Mapping distributed sources of cortical rhythms in mild Alzheimer's disease. A multicentric EEG study," *Neuroimage,* vol. 22, p. 57–67, 2004.

[26] Lehmann C, Koenig T, Jelic V, Prichep L, John RE, Wahlund LO, Dodge Y, Dierks T, "Application and comparison of classification algorithms for recognition of Alzheimer's disease in electrical brain activity (EEG)," *Journal of neuroscience methods,* vol. 161, no. 2, pp. 342-350, 2007.

[27] Cichocki A, Shishkin SL, Musha T, Leonowicz Z, Asada T, Kurachi T, "EEG filtering based on blind source separation (BSS) for early detection of Alzheimer's disease," *Clin Neurophysiol,* vol. 116, p. 729–37, 2005.

[28] Melissant C, Ypma A, Frietman EE, Stam CJ, "A method for detection of Alzheimer's disease using ICA-enhanced EEG measurements," *Artif Intell Med,* vol. 33, p. 209–22, 2005.

[29] Ahmadlou M, Adeli H, Adeli A, "New diagnostic EEG markers of the Alzheimer's disease using visibility graph," *J Neural Transm,* vol. 117, no. 9, p. 1099-1109, 2010.

[30] Amezquita-Sanchez JP, Mammone N, Morabito FC, Marino S, Adeli H, "A novel methodology for automated differential diagnosis of mild cognitive impairment and the Alzheimer's disease using EEG signals," *J. Neurosci. Methods,* vol. 322, p. 88–95, 2019.

[31] Kashefpoor M, Rabbani H, Barekatain M, "Automatic Diagnosis of Mild Cognitive Impairment Using Electroencephalogram Spectral Features," *J Med Signals Sens,* vol. 6, no. 1, pp. 25-32, 2016.

[32] Cassani R, Falk TH, Fraga FJ, Cecchi M, Moore DK, Anghinah R, "Towards automated electroencephalography-based Alzheimer's disease diagnosis using portable low-density devices," *Biomedical Signal Processing and Control,* vol. 33, p. 261–271, 2017.

[33] Maimon NB, Molcho L, Intrator N, Lamy D, "Single-channel EEG features during n-back task correlate with working memory load," *arXiv preprint arXiv:2008.04987,* 2020.

[34] Coifman RR, Wickerhauser MV, "Entropy-based algorithms for best basis selection," *IEEE Transactions on information theory,* vol. 38, no. 2, pp. 713-718, 1992.

[35] Neretti N, Intrator N, "An Adaptive approach to wavelets filter design," *IEEE Proceedings on Neural Networks for Signal Processing,* pp. 317-326, 2002.

[36] Crum RM, Anthony JC, Bassett SS, Folstein MF, "Population-based norms for the Mini-Mental State Examination by age and educational level," *Journal of the American Medical Association,* vol. 269, no. 18, p. 2386-91, 1993.

[37] O'Bryant SE, Humphreys JD, Smith GE, et al, "Detecting dementia with the mini-mental state examination in highly educated individuals," *Arch Neurol,* vol. 65, no. 7, p. 963-967, 2008.

[38] Virtanen P, Gommers R, Oliphant TE, et al, "SciPy 1.0: fundamental algorithms for scientific computing in Python," *Nature methods,* vol. 17, no. 3, p. 261–272, 2020.

[39] M. RD, "Confidence intervals from normalized data: A correction to Cousineau (2005)," *Reason,* vol. 4, no. 2, pp. 61-64, 2008.

[40] Lang L, Clifford A, Wei L, et al, "Prevalence and determinants of undetected dementia in the community: a systematic literature review and a meta-analysis," *BMJ Open,* vol. 7, p. e011146, 2017.

[41] Moretti DV, Frisoni GB, Fracassi C, Pievani M, Geroldi C, Binetti G, Rossini PM, Zanetti O, "MCI patients' EEGs show group differences between those who progress and those who do not progress to AD," *Neurobiol. Aging,* vol. 32, no. 4, pp. 563-571, 2011.

[42] N. Intrator, "Systems and methods for brain activity interpretation". USA Patent US20160235351A1, 2018.

[43] N. Intrator, "Systems and methods for analyzing brain activity and applications thereof". USA Patent US20170347906A1, 2019.

[44] Mateos-Pérez JM, Dadar M, Lacalle-Aurioles M, Iturria-Medina Y, Zeighami Y, Evans AC, "Structural neuroimaging as clinical predictor: A review of machine learning applications," *NeuroImage: Clinical,* vol. 20, pp. 506-522, 2018.

[45] Ghorbanian P, Devilbiss DM, Verma A, et al, "Identification of resting and active state EEG features of Alzheimer's disease using discrete wavelet transform," *Ann Biomed Eng,* vol. 41, no. 6, pp. 1243-1257, 2013.

[46] Tervaniemi M, Kujala A, Alho K, Virtanen J, Ilmoniemi RJ, Näätänen R, "Functional specialization of the human auditory cortex in processing phonetic and musical sounds: a magnetoencephalographic (MEG) study," *Neuroimage,* vol. 9, no. 3, pp. 330-336, 1999.

[47] Shiroky JS, Schipper HM, Bergman H, Chertkow H, "Can you have dementia with an MMSE score of 30?," *American Journal of Alzheimer's Disease and Other Dementias,* vol. 22, no. 5, p. 406-15, 2007.

[48] Khatun S, Morshed BI, Bidelman GM, "A Single-Channel EEG-Based Approach to Detect Mild Cognitive Impairment via Speech-Evoked Brain Responses," *IEEE Trans Neural Syst Rehabil Eng,* vol. 27, no. 5, pp. 1063-1070, 2019.

[49] Dauwels J, Vialatte F, Musha T, Cichocki A, "A comparative study of synchrony measures for the early diagnosis of Alzheimer's disease based on EEG," *NeuroImage ,* vol. 49, no. 1, p. 668–693, 2010.

[50] Jensen O, Tesche CD, "Frontal theta activity in humans increases with memory load in a working memory task," *European journal of Neuroscience,* vol. 15, no. 8, pp. 1395-1399, 2002.

[51] Scheeringa R, Petersson KM, Oostenveld R, Norris DG, Hagoort P, Bastiaansen MC, "Trial-by-trial coupling between EEG and BOLD identifies networks related to alpha and theta EEG power increases during working memory maintenance," *Neuroimage,* vol. 44, no. 3, pp. 1224-1238, 2009.

[52] Deiber MP, Meziane HB, Hasler R, et al, "Attention and Working Memory-Related EEG Markers of Subtle Cognitive Deterioration in Healthy Elderly Individuals," *J Alzheimers Dis,* vol. 47, no. 2, pp. 335-349, 2015.

[53] Missonnier P, Deiber MP, Gold G, et al, "Working memory load-related electroencephalographic parameters can differentiate progressive from stable mild cognitive impairment," *Neuroscience,* vol. 150, no. 2, pp. 346-356, 2007.

Appendix A: Methodological details

The data analysis methodology is composed of three steps:

1. Creation of a brain activity representation by novel Brain Activity Features (BAFs)
2. Creation of Novel Biomarkers based on the BAFs
3. Examination of the features on previously unseen data

Each of the steps is described below.

Creation of Brain Activity features (BAFs)

The creation of the Brain Activity Features (BAFs) occurs prior to application of the methodology onto the new data to be analyzed. Calculation of the BAFs is based on collecting a large cohort of high dynamic amplitude and frequency range single channel EEG data. The cohort includes multiple subjects that are exposed to different cognitive, emotional, and resting tasks. A schematic representation of the signal processing is depicted in Fig A1. The signal processing module is decomposing the EEG signal input into a large number of components which comprise the Brain Activity Features (BAFs). The output of the module is a Brain Activity Representation which is constructed based on the BAFs for any given EEG signal.

Figure A1. schematic representation of the construction of the Brain Activity Features (BAFs). See text for the description of the different steps.

A: electrophysiological signal input

The EEG cohort described above is the input of the signal processing algorithm presented as the first step of the process.

B: Wavelet Packet Analysis

For a given cohort of EEG recordings, a family of *wavelet packet trees* is created. For the mathematical description, we follow the notation and construction provided in chapters 5, 6 and 7 of Wickerhauser's book[1].

To demonstrate the process; let *g* and *h* be a set of *biorthogonal quadrature filters* created from the filters *G* and *H* respectively. Each of these is a convolution-decimation operator, where in the case of the simple *Haar* wavelet, *g* is a set of averages and *h* is a set of differences.

The construction of the full wavelet packet tree is by successive application of these functions (Figure A2), so that at every level, a new full orthogonal decomposition of the original signal *x* is created. In the classical wavelet decomposition by Daubechies[2], only the marked parts are used and the signal is decomposed into *Gx, GHx etc.,* but the full construction of the tree continues recursively, on *Gx, GHx* and so forth, to create a full binary tree. Coifman and Wickerhauser[3] observed that a large number of orthogonal decompositions can be constructed from the full tree by mixing between the different levels and different blocks of the tree, following a simple rule. The recursive construction of the full tree is described next.

Figure A2. Construction of a Discrete Wavelet Transform Tree (Taken from Wickerhauser[1]). The top panel represents the classical wavelet construction and the bottom panel extends the construction to a full wavelet packet tree.

Let ψ_1 be the *mother wavelet* associated to the filters $s \in H$, an $d \in G$. Then, the collection of *wavelet packets* ψ_n, is given by:

$$\psi_{2n} = H\psi_n; \qquad \psi_{2n}(t) = \sqrt{2}\sum_{j \in Z} s(j)\psi_n(2t - j),$$

$$\psi_{2n+1} = G\psi_n; \qquad \psi_{2n+1}(t) = \sqrt{2}\sum_{j \in Z} d(j)\psi_n(2t - j).$$

The recursive form provides a natural arrangement in the form of a binary tree (Figure A2). The functions ψ_n have a fixed scale. A library of wavelet packets of any scale s, frequency f, and position p is given by:

$$\psi_{sfp}(t) = 2^{-s/2}\psi_f(2^{-s}t - p).$$

The wavelet packets $\{\psi_{sfp} : p \in Z\}$ are an orthonormal basis for every f (under orthogonality condition of the filters H and G) and are called *orthonomal wavelet packets*.

Using this construction, Coifman and Wickerhauser applied the *best basis* algorithm[3] to search for an orthonormal base that satisfies a specific optimality condition. The optimality condition that was chosen is Shannon's entropy of the coefficients of each component (or wavelet packet atom). It is a measure that prefers coefficients with a distribution that is far from uniform, in the sense that it prefers a distribution with a small number of high value coefficients and a long tale, namely, a large number with low value coefficients. The full details of the best basis search are described in chapter 7 of Wickerhaser's book.

The process of creating a best basis from the wavelet packet tree can be further iterated by an optimization on the mother wavelet using a gradient descent in wavelet space as is described in Neretti and Intrator[4].

C: Pruning the optimal representation

The outcome of the best basis algorithm is an orthogonal decomposition that is adapted to the stochastic properties of the collection of EEG signals. However, there is a risk that the decomposition is "overfitting" namely it is too adapted to the EEG signals from which it was created. To avoid this phenomenon, we first have to get rid of "small" coefficients. This can be done by the denoising technique of Coifman and Donoho[5]. The next step is introducing a validation set, which is another collection of EEG-recordings that was not used in the creation of the best basis. Using this set, we can determine which atoms maintain a high energy (some large coefficients) when decomposing the new signals. These atoms will remain in the representation. At the end of this part, the resulting set of decomposing signal contains only a part of the full orthonormal basis that was found. We then reorder the basis components not based on the binary tree that created them, but based on the correlation between the different components In this way, we created a brain activity representation in which components that are more correlated to each other, are also geographically close to each other within the representation. This is done for the purpose of improved visualization.

D: brain activity representation output

The result of the signal processing module is the brain activity representation. Specifically, it is a collection of 121 energy components, emanating from the wavelet packets as well as standard frequency bands which are updated each second. The representation (D) shows a color heatmap of each of the 121 X time matrix, so that the x axis represents time and the y axis represents the different components.

Creation of Novel features based on the BAFs

The signal components, which we termed BAFs, were constructed from single EEG channel recordings in an unsupervised manner, namely, there were no labels attached to the recordings for the purpose of creating the decomposition. To create biomarkers based on the BAFs, task labels are used, indicating the nature of cognitive, emotional, or resting challenge the subject is exposed to during the recording.

Given labels from a collection of subjects, and the corresponding high-dimensional BAF data, a collection of models attempting to differentiate between the labels based on the BAF activity can be used. In the linear case, these models are of the form:

$$V_k(w, x) = \Psi\left(\sum_i w_i x_i\right),$$

where w is a vector of weights, and Ψ is a transfer function that can either be linear, e.g., $\Psi(y) = y,$ or sigmoidal for logistic regression $\Psi(y) = 1/(1 + e^{-y})$.

Figure A3. Supervised construction of different features from labeled brain activity representation of different cognitive and non-cognitive tasks.

For each predictor, which we term biomarker, a standard machine learning procedure is applied as follows:

1. Choose a labeled data set with at least two different tasks (e.g. cognitive, emotional, or resting challenge). The data set may include the same challenge but for a non-homogenous group.

2. Separate the data into three sets: training, validation, and test.

3. Choose a model to train on from a family of models that includes linear regression, linear regression with binary constrains (zero and one values for the weights), linear regression with only positive values, logistic regression, discriminant analysis and principal components analysis. In the non-linear models, use neural networks, support vector machine and the like.

4. Train each model on several sets of train/test and validation to best estimate internal model such as the variance constraints, on the ridge regression, the kernel size and number of kernels in a support vector machine, or the weight constraints in a neural network model.

5. From the above models, obtain predictors to be tested on other data with potentially other cognitive, emotional and rest challenges.

6. The last step in the process includes testing the biomarkers using a test data labeled set that was not used in the creation of these features. This allows removal of features that were overfitting to the training data, namely, they do not produce high significant difference on the validation data. This is still part of the model creation and not part of the model testing that is done on new data and is described in step 3.

All above steps are described in the scheme on Figure A3.

Examination of the features on previously unseen data

Following the creation of BAFs and the creation of features as described above, the features relevance can be tested on various cognitive or emotional challenge. The testing scheme is described in Figure A4. Specifically, data is collected with the sensor system and sent to the cloud for creation of a BAF representation using the previously determined wavelet packet atoms. The BAF representation is provided to previously determined ML models, which convert the BAF activity into features. Statistical tests are then applied to determine the quality of the predictions and the correlation of the features to the cognitive and emotional challenges that the participants undergo. This may include single subject analysis as well as group analysis.

Figure A4: Testing the relevance of the previously found features on the data.

In the process of testing the features on new data, we may want to get an *upper bound* to the performance of the feature, by seeking an *overfitting biomarker* on the currently tested data. This is only done to get an idea of the potential upper bound on prediction abilities from the existing data, and indirectly can tell us more about the optimality of the actual features that were constructed from a different data set and are assumed to be more general in this sense.

Appendix References

[1] Wickerhauser, M. V. (1996). Adapted wavelet analysis: from theory to software. CRC Press.

[2] Daubechies, Ingrid. (1988). "Orthonormal bases of compactly supported wavelets." Communications on pure and applied mathematics, 41(7): 909-996.

[3] Coifman, R.R., and M.V. Wickerhauser. (1992). "Entropy-Based Algorithms for Best Basis Selection." IEEE Transactions on Information Theory, 38(2): 713-718.

[4] Neretti N, Intrator N. (2002). An adaptive approach to wavelet filters design. Neural Networks for Signal Processing. Proceedings of the 2002 12th IEEE Workshop on IEEE.

[5] Coifman R.R. and D. L. Donoho. (1995). "Translation-Invariant De-Noising." Wavelets and Statistics, 125-150.